Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001140361-17-001415
Filing Date
2017-01-10
Accepted
2017-01-10 19:10:05
Documents
2
Period of Report
2017-01-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 doc1.html 3  
1 FORM 3 doc1.xml 3 2835
2 poa_kaye.htm EX-24 9332
  Complete submission text file 0001140361-17-001415.txt   13513
Mailing Address C/O KERYX BIOPHARMACEUTICALS 750 LEXINGTON AVENUE NEW YORK X1 10022
Business Address
Kaye Jack (Reporting) CIK: 0001376099 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36294 | Film No.: 17521717

Mailing Address MEIBERGDREFF 61 AMSTERDAM P7 1005 BA
Business Address MEIBERGDREFF 61 AMSTERDAM P7 1005 BA 31-20-5667394
uniQure N.V. (Issuer) CIK: 0001590560 (see all company filings)

EIN.: 000000000
SIC: 2834 Pharmaceutical Preparations